Key Insight
Purity greater than or equal to 99% is estimated to lead product at 64.0% share in 2026, followed by pharmaceutical grade as projected to secure 57.0% share of grade in 2026. Adoption rests on reproducible assay records and dependable lot release, with customer concentration and limited addressable volumes forming principal barriers.